MedPath

A multicentre, randomized, single-blind, parallel-controlled study of acupoint catgut embedding for metabolic fatty liver disease

Phase 1
Recruiting
Conditions
Metabolic fatty liver disease
Registration Number
ITMCTR2100004943
Lead Sponsor
Shuguang Hospital affiliated to Shanghai Universtiy of Traditonal Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Meet MAFLD diagnostic criteria;
2. ALT and AST are 5 times lower than the upper limit of normal;
3. Between the ages of 18 and 65 years old, regardless of gender;
4. Not taking drugs related to THE treatment of MAFLD;
5. Signed informed consent.
5) Signing the informed consent.

Exclusion Criteria

1. Other acute or chronic liver diseases;
2. Patients with serious primary diseases such as heart, brain, kidney and hematopoietic system;
3. Patients with acute fatty liver of pregnancy, lipid deposition disease, focal fatty liver, hepatic adipose tumor, etc.;
4. Psychopaths;
5. Women who are pregnant or trying to become pregnant, breast-feeding women;
6. Unstable body weight (change > 5% in the first 3 months);
7. Patients with diabetes who are taking insulin or oral hypoglycemic drugs;
8. Current use of weight loss medications (e.g. Orlistat);
9. Patients with anaphylactic specific constitution;
10. Those who cannot strictly follow the treatment plan.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.